ClostraBio Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 3
Employees
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $3.5M
Latest Deal Amount
  • Investors
  • 3

ClostraBio General Information

Description

Operator of a bio pharma company intended to develop therapeutics for food allergies. The company is developing microbiome modulating therapeutics and commercializing small molecule formulations and dietary fibers that modulate the gut microbiome to confer protection against food antigens, enabling doctors to treat patients suffering from life-threatening food allergies effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Chicago, IL
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ClostraBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Seed Round 09-Jan-2018 $3.5M 00.00 Completed Generating Revenue
3. Angel (individual) 06-Jun-2017 00000 00000 Completed Startup
2. Accelerator/Incubator 02-Jun-2017 $40K Completed Startup
1. Accelerator/Incubator 01-Jan-2016 Completed Startup
To view ClostraBio’s complete valuation and funding history, request access »

ClostraBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a bio pharma company intended to develop therapeutics for food allergies. The company is developing microbio
Biotechnology
Chicago, IL
3 As of 2017
00.00
000000000 00.00

0000000

adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000 000000000
Brisbane, CA
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

00000000

od tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercit
0000 000000000
Rockville, MD
00 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ClostraBio Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aimmune Therapeutics Formerly VC-backed Brisbane, CA 000 00000 000000&0 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 00 00000 0000000000 0 00000
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
00000000 000000000 Formerly VC-backed Westlake Village, CA 000 00000 000000 - 000 00000
00000 000000000 Formerly VC-backed Boulder, CO 000 00000 000000&0 00000
You’re viewing 5 of 18 competitors. Get the full list »

ClostraBio Executive Team (2)

Name Title Board Seat Contact Info
Cathryn Nagler Ph.D Co-Founder & President
Jeffrey Hubbell Ph.D Co-Founder & Board Member
To view ClostraBio’s complete executive team members history, request access »

ClostraBio Board Members (1)

Name Representing Role Since
Jeffrey Hubbell Ph.D ClostraBio Co-Founder & Board Member 000 0000
To view ClostraBio’s complete board members history, request access »

ClostraBio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ClostraBio Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Joseph Mansueto Angel (individual) Minority 000 0000 000000 0
New Venture Challenge Accelerator/Incubator 000 0000 000000 0
Polsky Center Accelerator/Incubator 000 0000 000000 0
To view ClostraBio’s complete investors history, request access »